Search

Your search keyword '"Vree, Tom B."' showing total 213 results
Start Over Author "Vree, Tom B."
213 results on '"Vree, Tom B."'

1. Pharmacokinetics of enterolignans in healthy men and women consuming a single dose of secoisolariciresinol diglucoside

Author

Kuijsten, Anneleen, Arts, Ilja C.W., Vree, Tom B., and Hollman, Peter C.H.

Subjects
Pharmacokinetics -- Research, Food/cooking/nutrition
Abstract

High concentrations of enterolignans in plasma are associated with a lower risk of acute coronary events. However, little is known about the absorption and excretion of enterolignans. The pharmacokinetic parameters and urinary excretion of enterodiol and enterolactone were evaluated after consumption of their purified plant precursor, secoisolariciresinol diglucoside (SDG). Twelve healthy volunteers ingested a single dose of purified SDG (1.31 [micro]mol/kg body wt). Enterolignans appeared in plasma 8-10 h after ingestion of the purified SDG. Enterodiol reached its maximum plasma concentration 14.8 [+ or -] 5.1 h (mean [+ or -] SD) after ingestion of SDG, whereas enterolactone reached its maximum 19.7 [+ or -] 6.2 h after ingestion. The mean elimination half-life of enterodiol (4.4 [+ or -] 1.3 h) was shorter than that of enterolactone (12.6 [+ or -] 5.6 h). The mean area under the curve of enterolactone (1762 [+ or -] 1117 nmol/L x h) was twice as large as that of enterodiol (966 [+ or -] 639 nmol/L x h). The mean residence time for enterodiol was 20.6 [+ or -] 5.9 h and that for enterolactone was 35.8 [+ or -] 10.6 h. Within 3 d, up to 40% of the ingested SDG was excreted as enterolignans via urine, with the majority (58%) as enterolactone. In conclusion, a substantial part of enterolignans becomes available in the blood circulation and is subsequently excreted. The measured mean residence times and elimination half-lives indicate that enterolignans accumulate in plasma when consumed 2-3 times a day and reach steady state. Therefore, plasma enterolignan concentrations are expected to be good biomarkers of dietary lignan exposure and can be used to evaluate the effects of lignans. KEY WORDS: * enterodiol * enterolactone * lignans * secoisolariciresinol diglucoside * bioavailability

Published
2005

24. Adverse reactions to co-trimoxazole in HIV infection

Author

Van der Ven, Andre J.A.M., Koopmans, Peter P., Vree, Tom B., and Van der Meer, Jos W.M.

Subjects
Co-trimoxazole -- Adverse and side effects, HIV infection -- Complications, Pneumocystis carinii pneumonia -- Drug therapy, AIDS (Disease) -- Complications, Sulfonamides -- Adverse and side effects
Published
1991

25. Abstracts of papers

Author

van Oort, W. J., Kerkhofs, B., van Dijk, A., van der Houwen, O. A. G. J., Hulshoff, A., Indemans, A. W. M., Reijenga, J. C., Gaykema, A., Mikkers, F. E. P., Leeuwenkamp, O. R., Jousma, H., van der Mark, E. J., Bult, A., van Iersel, W., Drenth, B. F. H., Ghijsen, R. T., de Zeeuw, R. A., Holthuis, J. J. M., Sijstermans, A. W., Römkens, F. M. G. M., Weller, E. B. C. M., Pinedo, H. M., McVie, J. G., Barends, P. M., Smits, M. H., Blauw, J. S., den Hartigh, J., Driebergen, R. J., Schijns, J. E. M. A., Underberg, W. J. M., Lake, O. A., Lingeman, H., Underberg-Chitoe, U. K., Wilting, J., Jagersma, T., Hoogvliet, J. C., Elferink, F., Hermans-Lokkerbol, A. C. J., van Bennekom, W. P., Werkhoven-Goewie, C. E., de Ruiter, C., Brinkman, U. A. Th., Frei, R. W., de Vries, G., van de Calseyde, J. F., van der Veeken, J., Verheggen, Th. P. E. M., Everaerts, F. M., van der Vijgh, W. J. F., van der Lee, H. B. J., Postma, G. J., Vree, Tom B., Hekster, Chiel A., Oosterbaan, Marijn M. J., Termond, Emiel F. S., Schoots, A. C., Cramers, C. A., Poppe, H., van de Vaart, F. J., Claessens, H. A., van Thiel, M., Westra, P., Labout, J. J. M., Bruins, A. P., and Drenth, B. F. H.

Published
1982
Full Text
View/download PDF

29. Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study†

Author

Schoenmakers, Karin P W, Vree, Tom B, Jack, Nigel T M, Bemt, Bart, Limbeek, Jacques, and Stienstra, Rudolf

Subjects
Adult, Male, Adolescent, Anterior Cruciate Ligament Reconstruction, Dose-Response Relationship, Drug, Epinephrine, Nerve Block, Pilot Projects, Middle Aged, Amides, Sciatic Nerve, Random Allocation, Young Adult, Humans, Vasoconstrictor Agents, Drug Interactions, Drug Therapy, Combination, Female, Ropivacaine, Anesthetics, Local, Femoral Nerve
Abstract

No pharmacokinetic data exist on doses of ropivacaine larger than 300 mg for peripheral nerve block in man, although in clinical practice higher doses are frequently used. The purpose of the present study was to describe the pharmacokinetic profile in serum of 450 mg ropivacaine with and without epinephrine in patients undergoing anterior cruciate ligament reconstruction.Twelve patients were randomly allocated to receive a single shot combined sciatic/femoral nerve block with 60 ml of either ropivacaine 0.75% alone (group R, n = 6) or ropivacaine 0.75% plus epinephrine 5 μg ml(-1) (group RE, n = 6). Venous blood samples for total and free ropivacaine serum concentrations were obtained during 48 h following block placement. Pharmacokinetic parameters were calculated using a non-compartmental approach.Results are given as mean (SD) for group R vs. group RE (95% CI of the difference). Total Cmax was 2.81 (0.94) μg ml(-1) vs. 2.16 (0.21) μg ml(-1) (95% CI -0.23, 1.53). tmax was 1.17 (0.30) h vs. 1.67 (0.94) h (95% CI -1.40, 0.40). The highest free ropivacaine concentration per patient was 0.16 (0.08) μg ml(-1) vs. 0.12 (0.04) μg ml(-1) (95% CI -0.04, 0.12). t(1/2) was 6.82 (2.26) h vs. 5.48 (1.69) h (95% CI -1.23, 3.91). AUC was 28.35 (5.92) μg ml(-1) h vs. 29.12 (7.34) μg ml(-1) h (95% CI -9.35, 7.81).Free serum concentrations of ropivacaine with and without epinephrine remained well below the assumed threshold of 0.56 μg ml(-1) for systemic toxicity. Changes in pharmacokinetics with epinephrine co-administration did not reach statistical significance.

Published
2012

34. Title Page / Contents / Preface

Author

Vree, Tom B., primary, Hekster, Yechiel A., additional, Termond, Emiel F. S., additional, Tijhuis, Marian W., additional, Nouws, Jacques F. M., additional, and Dorrestein, Gerrie, additional

Full Text
View/download PDF

40. High-performance Liquid-chromatographic-Atmospheric-pressure Chemical-ionization Ion-trap Mass-spectrometric Identification of Isomeric C6-hydroxy and C20-hydroxy Metabolites of Methylprednisolone in the Urine of Patients Receiving High-dose Pulse Therapy

Author

Vree, Tom B, primary, Maljers, Louis, additional, Van Den Borg, Noud, additional, Nibbering, Nico M M, additional, Verwey-Van Wissen, Corrien P W G M, additional, Lagerwerf, Aart J, additional, Maes, Robert A A, additional, and Jongen, P Jozef H, additional

Published
1999
Full Text
View/download PDF

45. Ergot Alkaloids

Author

N.J.A. de Groot, Akosua, primary, van Dongen, Pieter W.J., additional, Vree, Tom B., additional, Hekster, Yechiel A., additional, and van Roosmalen, Jos, additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results